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A B S T R A C T   
Background: We tested the real-world effectiveness of a collaborative task-sharing model on depressive symptom 
reduction in hypertensive Primary Health Care (PHC) patients in South Africa. 
Method: A pragmatic parallel cluster randomised trial in 20 clinics in the Dr Kenneth Kaunda district, North West 
province. PHC clinics were stratified by sub-district and randomised in a 1:1 ratio. Control clinics received care as 
usual (CAU), involving referral to PHC doctors and/or mental health specialists. Intervention clinics received 
CAU plus enhanced mental health training and a lay counselling referral service. Participant inclusion criteria 
were ≥ 18 years old, Patient Health Questionnaire-9 (PHQ-9) score ≥ 9 and receiving hypertension medication. 
Primary superiority outcome was ≥ 50% reduction in PHQ-9 score at 6 months. Statistical analyses comprised 
mixed effects regression models and a non-inferiority analysis. Trial registration number: NCT 02425124. 
Results: Between April 2015 and October 2015, 1043 participants were enrolled (504 intervention and 539 
control); 82% were women; half were ≥ 55 years. At 6 and 12 months follow-up, 91% and 89% of participants 
were interviewed respectively. One control group participant committed suicide. There was no significant dif-
ference in the primary outcome between intervention (N=256/456) and control (N=232/492) groups (55.9% 
versus 50.9%; adjusted risk difference = -0.04 ([95% CI = -0.19; 0.11], p = 0.6). The difference in PHQ-9 scores 
was within the defined equivalence limits at 6 and 12 months for the non-inferiority analysis. 
* Corresponding author at: Centre for Rural Health and School of Applied Human Sciences, University of KwaZulu- Natal, South Africa. Howard College, Mazisi 
Kunene Avenue, Durban, 4001, South. 
E-mail addresses: peterseni@ukzn.ac.za (I. Petersen), lara.fairall@uct.ac.za (L. Fairall), babalwa.zani@uct.ac.za (B. Zani), Arvin.Bhana@gmail.com (A. Bhana), 
Carl.Lombard@mrc.ac.za (C. Lombard), naomifolb@gmail.com (N. Folb), selohilweone@gmail.com (O. Selohilwe), daniella.georgeu-pepper@uct.ac.za 
(D. Georgeu-Pepper), petrus@ukzn.ac.za (R. Petrus), Mntambo@ukzn.ac.za (N. Mntambo), kathree@ukzn.ac.za (T. Kathree), M.Bachmann@uea.ac.uk 
(M. Bachmann), naomi.levitt@uct.ac.za (N. Levitt), graham.thornicroft@kcl.ac.uk (G. Thornicroft), crick.lund@uct.ac.za (C. Lund).   
† Joint first authors. 
Contents lists available at ScienceDirect 
Journal of Affective Disorders 
journal homepage: www.elsevier.com/locate/jad 
https://doi.org/10.1016/j.jad.2020.12.123 
Received 11 August 2020; Received in revised form 21 October 2020; Accepted 24 December 2020   
Journal of Affective Disorders 282 (2021) 112–121
113
Limitations: The trial was limited by low exposure to depression treatment by trial participants and by observed 
co-intervention in control clinics 
Conclusions: Incorporating lay counselling services within collaborative care models does not produce superior 
nor inferior outcomes to models with specialist only counselling services. 
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Introduction 
While South Africa’s health care system has been severely con-
strained by the HIV crisis over the past decade, a silent non- 
communicable disease epidemic has been growing. Hypertension is 
estimated to affect 20% of the adult population (Steyn et al., 2001). This 
is concerning given that uncontrolled hypertension is a risk for cardio-
vascular disease (CVD) (Zhou et al., 2018), and is the leading cause of 
death globally, with three-quarters of deaths due to CVD occurring in 
low- and middle-income countries (LMICs) (World Health Organization, 
2017). Comorbid depression independently increases risk of cardiovas-
cular events in at-risk populations (Jackson et al., 2018). In the context 
of high rates of hypertension, and depression being the most common 
individual common mental disorder 
(Tomlinson et al., 2009); identification and management of comor-
bid depressive symptoms in patients with hypertension attending pri-
mary health care (PHC) services could help improve health outcomes of 
this population. 
The PRogramme for Improving Mental health carE (PRIME) was a 
multinational research consortium focused on the development, imple-
mentation and scaling up of integrated primary mental health care at the 
district level in five LMICs (Lund et al., 2012). Working in partnership 
with the South African Department of Health, patients and community 
representatives, PRIME co-developed a collaborative care model that 
included a lay-counselling service within PHC clinics for treating 
depressive symptoms in patients with chronic conditions. Collaborative 
care for comorbid depressive symptoms in patients with chronic con-
ditions is effective in improving mental and physical health outcomes in 
high-income countries (Katon et al., 2010). There is a need for evidence 
of the effectiveness of such models in real-world LMIC settings. 
The PRIME model in South Africa, described elsewhere (Petersen 
et al., 2016), entailed strengthening of i) PHC nurses’ capacity to iden-
tify depressive symptoms in chronic care patients through additional 
training; and ii) referral systems to include facility-based lay counsellors 
trained and supervised to deliver manualized evidence-based counsel-
ling using cognitive behavioural techniques and problem solving (Dua 
et al., 2011). The latter was in addition to care as usual (CAU) which 
comprised established, albeit limited, referral pathways to doctors 
responsible for initiating antidepressant medication, and mental health 
specialists (sessional psychiatrists and district-based psychologists), who 
provided specialist referral services. A pilot study involving a repeat 
cross-sectional survey in four clinics, as well as a comparison group 
cohort study, found greater identification and referral of patients with 
comorbid depressive symptoms after the intervention; and an 
improvement in patient-level depressive symptoms in referred patients 
(Petersen et al., 2019). 
We report on a pragmatic cluster randomised controlled trial of the 
scale-up of this model as part of routine PHC. The primary aim of the 
study was to test the hypothesis that the PRIME collaborative model 
would be more effective than CAU for patients with hypertension and 
comorbid depressive symptoms and would improve both depressive 
symptoms and blood pressure control. Administrative and funding in-
formation required by the SPIRIT checklist (Chan et al., 2013) can be 




The study site was the Dr Kenneth Kaunda (DKK) district in the North 
West province of South Africa, west of the Gauteng industrial hub of 
South Africa. DKK was a National Health Insurance pilot site where a 
number of health system reforms were initiated including the Ideal 
Clinic which included Integrated Clinical Services Management (ICSM) 
for patients with chronic conditions (Department of Health, 2016). The 
formative evaluation and piloting of the collaborative care model also 
occurred in DKK and was used by the district to inform the development 
of a district mental health care plan that foregrounded decentralizing 
and increasing access to mental health care at PHC facilities. DKK is 
fairly representative of districts in South Africa, with a combination of 
smaller cities, towns and rural areas, and has a population of 796,823 
(Petersen et al., 2016), with the main economic activities being gold and 
platinum mining and agriculture. 
Study Design 
A pragmatic two-group parallel cluster randomised controlled trial 
was undertaken between April 2015 and October 2016. The cluster 
randomised design was adopted to avoid contamination between 
intervention and control group participants, as the intervention was 
implemented at the level of the PHC clinics. Data were collected in 
parallel with a sister trial, (CobALT - Comorbid Affective Disorders, 
AIDS/HIV, and Long Term Health), which evaluated the impact of the 
same intervention on depressive symptoms and viral load outcomes in 
HIV-positive patients on antiretroviral treatment in DKK as well as in the 
neighbouring Bojanala Platinum district (Fairall et al., 2018). Partici-
pant recruitment and baseline data collection began in the control 
clinics 3 months prior to the intervention clinics to provide for a short 
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embedding period of the model in the intervention clinics. 
The clinics were the unit of randomisation, with data collected on 
individual participants. Patient participants were recruited indepen-
dently of the trial intervention being tested, in line with the highly 
pragmatic orientation of the trial - which aimed to test the model in its 
completion, from identification through to management of depressive 
symptoms. 
In addition to the primary analysis assessing superiority, and before 
completion of data collection and analysis, ethics approval was obtained 
to conduct a secondary non-inferiority analysis of the main outcome 
findings. This was added in the event of a null finding of the superiority 
analysis to assess whether the intervention did not cause harm. The 
criteria for interpreting a superiority trial as a non-inferiority trial 
(Lewis, 2001) were met, namely: i) known effectiveness of the 
comparator, where referral was to doctors for antidepressant medication 
initiation, and mental health specialists (the model of CAU in the control 
group) (Archer et al., 2012); and ii) the choice of the non-inferiority 
margin being objective and widely accepted (Lewis, 2001), with Pa-
tient Health Questionnaire-9 (PHQ-9), (the main outcome measure), 
having established non-inferiority margins (Richards et al., 2016; Saxon 
et al., 2017). Ethical approval for the study was obtained from the 
University of KwaZulu-Natal’s Biomedical Research Ethics Committee 
(BREC) (BFC049/15); the University of Cape Town’s Faculty of Health 
Sciences Human Research Ethics Committee (HREC: 412/2011); as well 
as the North West Department of Health. Data safety and monitoring was 
overseen by the Data Safety and Monitoring Board (DSMB) established 
for the sister CobALT trial (Fairall et al., 2018). All amendments to the 
protocol were approved by BREC and amended on the trial registries. 
More details on approval, consent processes, data safety and monitoring 
have been published (Petersen et al., 2018). 
Description of services at intervention and control clinics 
Care as usual clinics 
All clinics were exposed to CAU. This was an integrated chronic care 
approach that included reorganization of chronic care services from 
verticalized to integrated services as part of South Africa’s national 
ICSM strategy (Mahomed et al., 2014). This included the introduction of 
a clinical decision support tool called Primary Care 101 (PC101) [later 
called Adult Primary Care (APC) and internationally, the Practical 
Approach to Care Kit (PACK)] (Fairall et al., 2018). This tool integrates 
the management of communicable and non-communicable diseases, 
mental illness, and women’s health. APC was rolled out to all NHI pilot 
districts, including DKK through 12 facility-based, short (1.5-2 hours) 
interactive training sessions (including two sessions on mental health). 
Patients identified with depressive symptoms were referred for treat-
ment to: i) PHC doctors for antidepressant medication initiation; ii) two 
district-based psychologists providing outreach counselling services to 
PHC clinics; and iii) the Psychology Outpatient Clinic based at the dis-
trict hospitals serviced by four psychologists at the time of the trial. A 
982-bed provincial tertiary specialist psychiatric hospital was also 
available for patients with severe mental illness requiring 
hospitalisation. 
Intervention clinics 
In addition to CAU, intervention clinics were exposed to i) Supple-
mentary training provided to PHC nurses comprising four additional 
APC sessions on mental health content, and four sessions on clinical 
communication skills (CCS). The APC mental health training mirrored 
the DoH cascade model of training, whereby master trainers trained 
facility-based trainers to provide on-site training to PHC nurses, while 
CCS training was provided by external CCS specialists; ii) Two work-
shops held with PHC doctors (appointed to PHC clinics as part of the NHI 
piloting process) responsible for initiating antidepressant treatment, to 
orientate them to the importance of treatment for depressive symptoms; 
and iii) Referral pathways that were strengthened through the 
introduction of lay counselling services in each of the 10 intervention 
clinics. The lay counsellors (N=14, including replacement counsellors) 
were trained and supervised to provide manualized evidence-based 
counselling for patients with depressive symptoms under the supervi-
sion of a project-employed clinical psychologist. Lay counsellors, with a 
minimum of 12 years of schooling, were consequently selected, trained 
and employed to provide this service for the duration of the trial. 
Randomisation and blinding 
The largest 20 primary care clinics (excluding the four clinics 
involved in the PRIME pilot study) out of all 60 clinics in the DKK district 
were enrolled in the trial (Fig. 1). All the enrolled clinics reported more 
than 10 000 patient attendances annually. Randomisation of the clinics 
was done by the trial statistician using nQuery Advisor before inter-
vention implementation or data collection. Clinics were stratified by 
sub-district into two strata to avoid bias arising from differences in sub- 
districts; and then randomised in each stratum into one of two parallel 
groups, with ten in each group. Staff in the intervention clinics were not 
blinded to intervention status because they were recipients of the 
training intervention. Blinding of fieldworkers could also not be guar-
anteed given implementation activities of the intervention even though 
they were not in informed of clinic status. All fieldwork activities were 
standardised across both groups with training manuals, standard oper-
ating procedures and daily supervision (Petersen et al., 2018). 
Enrolment procedure 
Patients attending the clinics for chronic conditions were invited to 
be assessed for eligibility for the study through information provided 
verbally in waiting rooms (with no mention of mental health or hyper-
tension). These volunteers were asked, in a private space, if they were 
≥18 years, and were on hypertension treatment. Patients who met these 
eligibility criteria were then administered the PHQ-9 following verbal 
pre-consent to be screened in a private room. Those screening positive, 
using a locally validated cut-off for chronic care patients of ≥ 9 on the 
PHQ-9 (Bhana et al., 2015), were provided with verbal and written in-
formation about the study in either Setswana, English or Afrikaans, and 
signed consent/ used a thumbprint as their signature. Patients were 
excluded if they needed urgent medical attention; were too ill to provide 
informed consent; or planned to move outside the area during the 
12-month follow-up period (Petersen et al., 2018). Patients scoring 
positive on item 9 of the PHQ-9 (that explores thoughts in the past two 
weeks of being better off dead or of self-harm), received 
psycho-educational material on suicidality and where to get help. In 
addition, at baseline and 6 months follow-up, participants were referred 
to a PHC nurse for further assessment and treatment if they reported 
having these thoughts for ≥ 8 days over two weeks. These referrals rules 
were changed at 12 months follow-up to improve accuracy. Participants 
who reported having these thoughts >0 days were asked an additional 5 
questions (whether they had a suicide plan, had deliberately injured 
themselves without intending to kill themselves, had attempted suicide 
in the past month and/or in their lifetime). If they answered yes to ≥1 of 
these questions they were given a referral. 
Sample size 
An intra-clinic correlation coefficient of 0.04 was used for the pri-
mary outcome of a 50% improvement in PHQ-9 score at 6 months 
compared with enrolment. This was based on a similar trial in a LMIC 
(Rahman et al., 2008); significance level of 0.05; and estimated loss to 
follow-up of 20%. For the superiority analysis, a sample size comprising 
50 patients in each of the 20 clinics making up 1000 patients (500 pa-
tients in the intervention group and 500 patients in the control group) 
was estimated to provide 90% power to detect a risk difference of 17% 
(60% control versus 77% intervention), and 80% power to detect a risk 
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difference of 15% (60% control versus 75% intervention). This cluster 
based sample size was also sufficient to power the equivalence analysis, 
with at least 80% power for a two-one-sided test for equivalence of the 
mean PHQ-9 scores at 6 and 12 months based on the margins of -1.9 to 
1.9 units; a standard deviation of 5 units; and inflation factor (IF) of 2.96 
(IF=1+(50-1)x0.04). For the non-inferiority sample size assumptions, 
the individual randomised sample size was 151 per group, and hence 
applying the IF the required sample size was 447 per group. Further 
sample size estimates are reported in the protocol (Petersen et al., 2018). 
Data collection and outcome measures 
Enrolled participants were administered the baseline questionnaire 
in either Setswana, Afrikaans or English. Fieldworkers used tablets to 
collect data electronically that were uploaded daily onto a secure server. 
Details of the selection, training and supervision of the fieldworkers, 
data management and participant stipends are reported in the protocol 
(Petersen et al., 2018). In addition to the PHQ-9, the baseline ques-
tionnaire included demographic questions, anthropometric 
Fig. 1. Consort Diagram.  
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measurements (height, weight, waist circumference and blood pres-
sure), World Health Organization Disability Assessment Schedule 2.0 
(WHODAS 2.0), Perceived Stress Scale, healthcare utilisation including 
clinic visits, and hospital admissions. Mortality data were acquired 
through families of participants once participants had defaulted on 
follow-up interviews. Detailed information on these measures have been 
reported in the protocol (Petersen et al., 2018). Independently of the 
trial outcomes, process indicators monitoring the intervention imple-
mentation were collected through clinical and project records, irre-
spective of whether patients were enrolled in the trial. 
Outcomes 
The primary outcome was the proportion of patients with at least 
50% reduction in PHQ-9 scores at 6 months follow-up compared to 
baseline. This primary outcome was adopted as per the protocol 
(Petersen et al., 2018) on the basis of being recommended and widely 
used as a measure of a clinically significant change (Kroenke et al., 2001; 
Huijbregts et al., 2013; IJff et al., 2007; Wernher et al., 2014; Unützer 
et al., 2002). Secondary outcomes were: other PHQ-9 outcomes (dif-
ference in mean scores, recovery, remission) at both 6 and 12 months 
(see Table 2); receipt of counselling (yes/no and from whom); receipt of 
antidepressant treatment; blood pressure measured by fieldworkers at 6 
and 12 months; and other risk factors for CVD including body mass 
index, waist circumference and smoking history. 
Statistical analyses 
The statistician was blinded to all data pertaining to the primary and 
secondary outcomes until the analysis was finalized. Analyses were 
conducted in Stata 13. Analyses comparing outcomes were by intention 
to treat. Missing data were not imputed, and participants with missing 
data were excluded from the analyses of those variables. Mixed effect 
regression models, in which stratum was included as a covariate and 
intra-cluster correlation of outcomes was accounted for by treating 
clinics as random effects. Binomial regression was used to estimate 
differences in proportions of participants considered having at least 50% 
reduction in depressive symptoms, measured using PHQ-9 at 6 months 
for the primary outcome and adjusted for baseline PHQ-9 scores. Sec-
ondary outcomes were analysed using binomial regression for binary 
outcomes, linear regression for numerical outcomes comparing values at 
follow-up adjusted for baseline values, and Poisson regression for count 
outcomes. 
For the non-inferiority analysis, the non-inferior clinical outcome 
was defined as the difference between groups in mean PHQ-9 symptom 
scores at 6 and 12 months within the equivalence limits of -1.9 to 1.9 
(90% confidence interval). As suggested by the Committee for Pro-
prietary Medicinal Products (2001), this was derived from previous 
non-inferiority trials using the PHQ-9 as the outcome measure (Richards 
et al., 2016; Saxon et al., 2017), and where a change difference of less 
than 2 on the PHQ-9 is not regarded to be clinically important (Saxon 
et al., 2017). We used mixed effect linear regression models adjusted for 
stratum, baseline PHQ-9 scores and for the cluster design to test for 
equivalence of differences in mean PHQ-9 scores between the two 
groups at 6 and 12 months. 
Results 
At enrolment, 3756 patients were screened and 1043 enrolled; 504 in 
10 intervention clinics and 539 in 10 control clinics. Excluded patients 
were either younger than 18 (5), not planning to reside in the study area 
during follow-up (14), did not give pre-consent (13), were not taking 
hypertension medication (760) or did not provide informed consent (32) 
(Fig. 1). All 20 clusters were followed up to the end of the trial: 456 
(90%) and 492 (91%) patients at 6 months; and 441 (88%) and 484 
(90%) patients at 12 months in the intervention and control groups, 
respectively. There were 23 (5%) deaths in the intervention group and 
14 (3%) in the control group at follow-up, with one suicide reported in 
the control group at 12-month follow-up. This suicide was not deemed to 
be related to the study procedure by the DSMB and BREC. 
The enrolment socio-demographic and clinical characteristics of the 
intervention and control groups are displayed in Table 1. The clinic 
baseline table is contained in the online supplementary File S1. 
The trial population was predominantly women in both intervention 
(85%) and control groups (79%), with 25% of participants in both 
groups reporting having never attended school. Employment levels were 
low (22% and 23% in the intervention and control groups respectively), 
with over half the sample in receipt of social grants (52% and 62% in the 
intervention and control groups respectively). At baseline, there were 
high levels of multimorbidity: 63% and 58% of participants had other 
chronic conditions in addition to depressive symptoms and hypertension 
in the intervention and control groups respectively. A third (33%) of 
Table 1 
Demographic and Clinical Enrolment characteristics of participants.  
Characteristic Intervention n 
(%), N=504 
Control n (%), 
N=539 
Proportion women 430 (85) 424 (79) 
Age in years: mean (SD); median (IQR) 54 (11); 54 (47, 
60) 
55 (11); 55 
(48, 62) 
PHQ-9 score: mean (SD); median (IQR) 13 (4); 13 (11, 15) 14 (4); 13 (11, 
16) 
PHQ-score=9 47 (9) 48 (9) 
PHQ-9 score category:   
9-14: mild/moderate 356 (71) 338 (63) 
15-27: moderately severe or severe 168 (29) 201 (37) 
Blood pressure   
Systolic blood pressure: mean (SD); median 
(IQR) 
136 (23); 133 
(120, 149) 
138 (24); 137 
(120, 152) 
BP ≥180/110 mmHg 59 (12) 81 (15) 
BP ≥140/90-179/109 mmHg 237 (47) 248 (46) 
BP <140/90 208 (41) 210 (39) 
Medical history   
Previous heart attack 98 (19) 97 (18) 
Previous stroke 50 (10) 45 (8) 
Previous heart attack or stroke 132 (26) 124 (23) 
History of diabetes 69 (14) 97 (18) 
History of depression 100 (20) 130 (24) 
On antiretroviral treatment 167 (33) 131 (24) 
Previous tuberculosis 98 (19) 97 (18) 
On antiretroviral treatment or previous 
tuberculosis 
204 (40) 186 (35) 
Smoking history   
Current smokers 44 (9) 94 (17) 
Pack year history: mean (SD); median (IQR) 9 (10); 6 (4, 9) 12 (16); 7 (4, 
14) 
BMI (kg/m2): mean (SD); median (IQR) 30 (9); 29 (24, 36) 30 (9); 29 (23, 
35) 
BMI category N=497 N=536 
BMI >30: Obese 241 (48) 241 (45) 
BMI ≤30: Not obese 256 (52) 295 (55) 
CVD risk percent >20% 139 (28) 201 (37) 
Reported a hospitalisation in the last 3 
months 
12 (2) 22 (4) 
World Health Organization disability 
assessment schedule 2 score1: mean (SD); 
median (IQR) 
10 (7); 9 (4; 13) 11 (8); 10 (4; 
16) 
Highest level of education achieved   
Never attended school 125 (25) 133 (25) 
Some primary school education 235 (47) 261 (48) 
Some secondary school or tertiary 
education 
144 (29) 145 (27) 
Employed or self employed 117 (23) 117 (22) 
Receiving a government social grant 264 (52) 336 (62) 
BMI=body mass index; BP =blood pressure; CVD=cardiovascular disease; 
IQR=interquartile range; PHQ-9= the 9-item patient health questionnaire; 
SD=standard deviation. 
1 Score out of 37, with a score of 0-1 considered no disability, and 2-37 
considerable disability (37 is the lowest level of functioning (Hanass-Hancock 
et al., 2015). 
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participants in the intervention group and a quarter (24%) in the control 
group were on antiretroviral treatment for HIV. More than half of par-
ticipants did not meet blood pressure targets at the time of the trial 
(<140/90 mmHg) in both the intervention (59%) and control groups 
(61%). There was minimal difference in mean PHQ-9 scores between 
groups at baseline, with the majority of participants in both groups 
having PHQ-9 scores falling in the moderate range (9-14) (71% and 63% 
in the intervention and control groups, respectively). A higher number 
of participants scored in the moderate-severe to severe symptoms range 
(15-27) in the control group (37%) compared to the intervention group 
(29%). High levels of disability were reflected by the WHODAS 2.0 
scores, with mean scores of 10 and 11 in the intervention and control 
groups respectively with a score >2 being indicative of disability 
(Hanass-Hancock et al., 2015). 
We present secondary treatment exposure results at 6 and 12 months 
first to elucidate the primary outcome findings. In relation to treatment 
exposure (see Table 2), only 11% of the intervention trial participants 
reported a referral to the clinic lay-counselling service over the trial 
period; and even fewer participants reported receipt of the service (7%). 
Receipt of lay-counselling was not associated with baseline PHQ-9 score, 
age, sex or any other variable recorded at baseline. While roughly equal 
numbers of participants received specialist services before the trial, this 
was not the case at 6 and 12 months follow-up, with a significantly 
greater number of control participants in receipt of such services at 12 
months. Receipt of antidepressant medication was minimal in both 
groups (see Table 2). 
In relation to the primary outcome, a small proportion of the inter-
vention group had ≥ 50% improvement in PHQ-9 scores at 6 months 
compared with enrolment (55.9% vs 50.9%). This was not significantly 
different in the primary analysis (risk difference = -0.04 ([95% CI =
-0.19; 0.11], p = 0.6) (See Table 3) or when additional enrolment 
measurements were included in the full model (See online Supplemen-
tary File S2). Sub-group analysis of intervention participants who 
received lay counselling revealed a similar reduction in PHQ-9 scores to 
the overall sample at 6 months follow-up compared with enrolment. 
The results of the non-inferiority analysis indicate that absolute 
PHQ-9 scores at 6 months follow-up were no worse in the intervention 
group compared to the control group (Intervention: mean 7.3 [SD 5.4], 
Control: 7.59 [SD 5.5], with an estimated adjusted mean difference of 
-0.10 PHQ-9 points [90% CI -1.51 to 1.31], p = 0.900). The same pattern 
was observed at 12 months (Intervention: mean 6.3 [SD 4.5], Control: 
7.04 [SD 4.8], with an estimated adjusted mean difference of -0.46 PHQ- 
9 points [90% CI -1.88 to 0.96], p = 0.583). The estimated 90% confi-
dence interval for the mean difference in the 6 and 12 months PHQ-9 
scores falls within the a priori defined non-inferiority limit of -1.9 to 
1.9, favouring the intervention group (Fig. 2). 
There were no differences between the intervention and control 
groups for any of the other secondary PHQ-9 outcomes at 6 and 12 
months (Table 2), except for new diagnosis of depressive symptoms at 
12 months (online Supplementary Table S6). Sub-group analysis of the 
effect of the intervention on depressive symptoms in participants with 
moderate symptoms (9-14) at baseline (online Supplementary files S3- 
S5) indicates a 75% chance of being in remission or having mild 
depressive symptoms at 6 months follow-up, with further improvement 
at 12 months follow-up. This contrasts with participants having a history 
of depression or who had moderately severe to severe depressive 
symptoms (15-27) at baseline; with roughly a third in this group still 
displaying moderately severe to severe symptoms at both 6 and 12 
months follow-up. 
Regarding secondary cardiovascular risk outcomes, there was a 
reduction in uncontrolled blood pressure in both groups at both 6 and 12 
months compared to baseline. However, the proportions of patients who 
failed to meet blood pressure targets was still high in both groups at both 
follow-up time points (Table 4). There were no significant differences in 
WHODAS 2.0 disability scores at 12-month follow-up. 
Other secondary outcomes are reported in Supplementary File S6. 
Significantly more participants in the control group were diagnosed 
with both depression and tuberculosis during the trial period compared 
to the intervention group. There were no differences in hospitalisations, 
mortality and adverse events at follow-up between the groups (See 
Table 5). 
Discussion 
In relation to the primary outcome, the collaborative care model 
incorporating lay counselling services did not result in a significant 
reduction in depressive symptoms in the intervention group compared 
to the control group. However, neither was it inferior. Being a pragmatic 
trial, participants were enrolled independently of exposure to the 
intervention. This enrolment process was unlike similar trials in South 
Africa, such as Project Mind, where enrolled patients were referred 
directly into the intervention being tested by study-employed research 
Table 2 




Treatment prior to the trial Treatment at 6 months Treatment at 12 months  





















4/504 (0.8) 0/539 

































at a therapeutic 
dose at any point         








antidepressants         







Referred to PRIME 
counsellor over 
12 months period         
57/504 
(11.3) 
0/539   
RD=risk difference. 
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assistants (Myers et al., 2018). This pragmatic approach, however, 
reduced the power of the trial to show a significant difference in the 
primary outcome. Independently of the trial data, referrals to the lay 
counsellors were recorded as part of the intervention. This process data 
reveals close to 1400 referrals to the lay counsellors in the intervention 
clinics during the trial period. However, only 11.3% and 5% of trial 
participants in the intervention group reported receiving referrals to 
either the clinic lay counsellors or mental health specialists respectively, 
suggesting a relatively low referral rate relative to patients presenting 
with depressive symptoms. Following Moore et al. (2015), an extensive 
process evaluation was conducted alongside the trial. This involved 
quantitative process variables to assess quality and fidelity of the 
implementation of the intervention that could have impacted on referral 
rates, as well as qualitative interviews with facility managers, providers 
and patients to understand causal mechanisms and identify contextual 
factors associated with variation between the outcomes of the clusters in 
the trial, including referral rates. These data are currently being ana-
lysed and reported in separate papers. Within this real-world context, 
there are, however, several possible explanations for these low referral 
rates. Organizationally, process data collected alongside the trial 
revealed that the nurse training in the PC101/APC mental health 
module provided by the facility-based trainers under real-world condi-
tions, was uneven across the clinics. This could be attributed to mental 
health not being a priority at the time of the trial - with the focus being 
on improving services to achieve priority targets, especially those linked 
with reducing the HIV burden. Provider factors, in particular nurse 
confidence in diagnosing depressive symptoms, in the absence of uni-
form exposure to the PC101/APC mental health module could have 
consequently played a role. Previous research suggests the importance 
of training to improve nurse confidence in diagnosing depression 
(McCabe et al., 2012). Regarding patient factors, low mental health 
literacy rates, associated with low educational levels (a quarter of par-
ticipants reported no schooling at baseline), could have impacted 
negatively on demand for mental health services (Saraceno et al., 2007). 
The null findings could also be a product of an observed co- 
intervention during the trial. As shown in Table 2, participants in the 
control clinics had greater exposure than participants in intervention 
clinics to district specialist mental health services during the trial. Par-
ticipants in the intervention clinics had, on the other hand, greater 
exposure to the task-shared lay counselling service. District specialist 
providers were observed to have focused their limited mental health 
specialist resources on servicing the control clinics during the trial, 
ostensibly to improve coverage of mental health services in PHC clinics 
overall in the district in line with the district mental health care plan; 
and made possible by the presence of project-employed lay counsellors 
in the intervention clinics. It has been argued previously that pragmatic 
trials have the potential for contamination despite cluster randomisation 
through unplanned co-interventions and other factors (Fairall et al., 
2017). 
This co-intervention did, however, render the trial suitable for con-
ducting a non-inferiority analysis. The results of this analysis indicate 
that the collaborative care model incorporating clinic lay counsellors did 
not introduce harm and produced outcomes as good as those of CAU 
where referrals were restricted to PHC doctors and mental health 
specialists. 
In contexts where global mental health trials of task-sharing have 
mostly been explanatory and focused on testing proof of concept (Singla 
et al., 2017); the findings of this pragmatic trial highlight the need to 
understand how to improve the adoption of task-sharing within routine 
services at PHC level. To this end, since the completion of the trial, in-
vestigators have engaged in implementation science research through 
the Southern African Mental health INTegration (SMhINT) project. More 
information can be found on www.crh.ukzn.ac.za. 
There were several noteworthy results concerning secondary out-
comes. Three-quarters of participants with moderate symptoms at 
baseline had minimal to mild symptoms (PHQ-9 score of < 9) at 6 
months, sustained at 12 months. However, roughly one-third of partic-
ipants with a history of depression, or moderately severe to severe 
symptoms at baseline, showed no improvement at 6 and 12 months. In 
the face of low treatment exposure, these findings are not surprising 
given a higher probability of spontaneous remission in people with 
milder depressive symptoms compared to those with severe symptoms 
(Whiteford et al., 2013). This calls for a targeted approach to depression 
treatment in PHC, prioritizing patients with more severe symptoms. In 
particular, the very low rates of reported antidepressant treatment at 12 
months for both intervention and control participants (see Table 2) need 
to be addressed. At the time of the study, PHC nurses could identify and 
Table 3 











Primary outcome N=456 N=492   
PHQ-9 response: 50% 
improvement in PHQ-9 
score at 6 months from 
baseline5 
275 (56) 232 (51) -0.04 (-0.19; 
0.11) 
0.595 
Secondary outcomes at 6 
months 
N=456 N=492   
PHQ-9 score at 6m: mean 
(SD); median (IQR)2 
7 (5); 6 (3, 
10) 





Severity of depressive 
symptoms at 6 months4     
PHQ-9 score 0-4: no 
depressive symptoms 
145 (32) 160 (33) 1.06 (0.54; 
2.08) 
0.866 
PHQ-9 score 5-9: mild 
depressive symptoms 
182 (40) 192 (39)   
PHQ-9 score 10-14: 
moderate depressive 
symptoms 
93 (20) 93 (20)   
PHQ-9 score 15-27: 
moderately severe 
depressive symptoms 
36 (8) 44 (6)   
Secondary outcomes at 12 
months 
N=441 N484   
PHQ-9 score at 12m: mean 
(SD); median (IQR)2 





PHQ-9 response at 12 
months: 50% 
improvement in PHQ-9 
score at 12 months from 
baseline5 
249 (56) 271 (56) 0.02 (-0.17; 
0.20) 
0.866 
Remission of depression 
symptoms: PHQ-9 score 
of ≤5 at 12 months3 
196 (44) 197 (41) 1.05 (0.65; 
1.69) 
0.854 
PHQ9 recovery: PHQ-9 
score of ≤5 at both 6 








Severity of depressive 
symptoms at 12 
months4     
PHQ-9 score 0-4: no 
depressive symptoms 
162 (37) 170 (35) 0.89 (0.43; 
1.86) 
0.764 
PHQ-9 score 5-9: mild 
depressive symptoms 
198 (45) 192 (40)   
PHQ-9 score 10-14: 
moderate depressive 
symptoms 
58 (13) 98 (18)   
PHQ-9 score 15-27: 
moderately severe 
depressive symptoms 
23 (5) 24 (7)   
IQR=interquartile range; PHQ-9= the 9-item patient health questionnaire; 
SD=standard deviation. 
1 Adjusted for trial design and baseline characteristics. 
2 Effect estimate coefficient; 
3 Effect estimate risk ratio. 
4 Effect estimate odds ratio; 
5 Risk Difference 
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refer patients for depression treatment, but were not authorized to 
initiate antidepressant medication. They had to refer patients to PHC 
doctors for antidepressant medication initiation. Besides the need to 
strengthen the capacity of PHC doctors to initiate antidepressant 
medication, they are a scarce resource, particularly outside of the main 
metropoles of South Africa. This highlights the need for professional 
PHC nurses to be authorized and capacitated to initiate antidepressant 
medication for moderate-severe and severe depressive symptoms as a 
matter of urgency. 
In relation to multimorbidity and cardiovascular risk, the study 
participants had substantial levels of multimorbidity and displayed poor 
blood pressure control, with a quarter already having had a cardiovas-
cular event. These findings are concordant with other South African 
studies (Berry et al., 2017; National Department of Health & South Af-
rican Medical Research Council, 2019), and highlight the need to 
improve blood pressure control to reduce stroke and ischaemic heart 
disease mortality - the second and fourth leading causes of mortality 
respectively in the country in 2012 (Pillay-van Wyk et al., 2016). 
Concerted efforts are required to improve treatment adherence to hy-
pertension medication. Targeted screening for moderate-severe to se-
vere depressive symptoms in patients with uncontrolled blood pressure 
(Folb et al., 2015) is recommended given a growing body of evidence of 
the role of comorbid depression in increasing risk for cardiovascular 
events (Cohen et al., 2015). 
Limitations 
Low exposure to the strengthened collaborative care model sub-
stantially reduced power to show a significant difference on the primary 
outcomes between the groups. The observed co-intervention of 
concentrating referral specialist mental health services in the control 
clinics to improve service coverage in the district also introduced bias 
into the study. 
Fig. 2. Non-inferiority margins for PHQ-9 scores at 6 and 12 months.  
Table 4 
Effect of the intervention on blood pressure, risks for cardiovascular disease and 
disability.  










Outcomes at 6 months N=456 N=492   
Systolic blood pressure 
at 6m: mean (SD); 
median (IQR) 








Blood pressure <140/ 
90 
233 (51) 281 (57) -0.08 (-0.15; 
0.002) 
0.057 
Blood pressure ≥140/ 
90 
223 (49) 211 (43)   
Outcomes at 12 months N=441 N=484   
Systolic blood pressure 
at 12m: mean (SD); 
median (IQR) 








Blood pressure <140/ 
90 
222 (50) 242 (50) -0.01 (-0.12; 
0.10) 
0.850 
Blood pressure ≥140 219 (50) 242 (50)   
Cardiovascular disease 
risk percent >20%1 






schedule 2 score2: 
mean (SD); median 
(IQR) 








IQR=interquartile range; SD=standard deviation. 
1 effect estimate=coefficient; 
2 Score out of 37, with a score of 0-1 considered no disability, and 2-37 
considerable disability (37 is the lowest level of functioning) 
Table 5 
Adverse events/outcomes at follow-up.  
Outcome Intervention n/ 









Mortality 13 (2.6) 10 (1.9) 0.01 (-0.01; 
0.03) 
0.462 
Death by suicide 0 (0) 1 (0.2)   
Number with a 
hospitalization 
20 (4.0) 34 (6.3) -0.02 (-0.05; 
0.01) 
0.136 
End of study 
referrals     
PHQ-9 score ≥20 
at 12 m 





33 (6.6) 59 (11.0) -0.04 (-0.11; 
0.02) 
0.187  
1 Adjusted for trial design and baseline characteristics. 
2 Uncontrolled hypertension= blood pressure≥160/100 at all measured time 
points or blood pressure≥180/110 at 12 months while on hypertension 
medication 
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Conclusion 
Collaborative care for comorbid depressive symptoms in patients on 
hypertension treatment that includes referral to clinic lay counsellors is 
neither superior nor inferior to referral to mental health specialists. The 
use of lay counsellors within a collaborative care approach to increase 
access to psychological treatments for depressive symptoms in contexts 
where specialist resources are scarce, is supported. A targeted approach 
to screening for moderate-severe to severe depressive symptoms in pa-
tients with uncontrolled hypertension is recommended. The low expo-
sure to any intervention in both groups of the trial highlights the need 
for implementation science research to enhance our understanding of 
how to improve identification and referral of comorbid depression in 
primary health care clinics – this being the first step in the treatment 
cascade. 
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